BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) arising in intraductal papillary mucinous neoplasms (IPMN) may represent a different biologic entity than classic PDAC, and there is little evidence to inform adjuvant treatment decisions. The purpose of this study was to identify prognostic factors for PDAC arising in IPMN and determine the benefit of postoperative adjuvant therapy. METHODS: Forty-four patients without previous therapy who underwent surgery for invasive PDAC arising in association with IPMN at our institution were identified. Medical records were reviewed for clinical and pathologic features, adjuvant therapy, and outcomes. RESULTS: On univariate analysis, positive nodes (hazard rate [HR] 14, 95% confidence interval [CI] 4.2-44), CA 19-9 > 80 (HR 6.2, 95% CI 2.2-17), lymphovascular invasion (HR 4.7, 95% CI 1.5-15), perineural invasion (HR 3.9, 95% CI 1.5-10), and positive margins (HR 3.1, 95% CI 1.2-8.0) were associated with inferior cancer-specific survival. Patients with positive nodes who received adjuvant therapy had higher median cancer-specific survival (20 months) than those who received no adjuvant therapy (3.3 months). CONCLUSIONS: Patients with PDAC arising in IPMN presented at an earlier stage than is reported for classical PDAC. Adjuvant chemoradiotherapy was associated with improved overall and cancer-specific survival for patients with advanced disease. These hypothesis-generating results require validation in a larger prospective trial.
BACKGROUND:Pancreatic ductal adenocarcinoma (PDAC) arising in intraductal papillary mucinous neoplasms (IPMN) may represent a different biologic entity than classic PDAC, and there is little evidence to inform adjuvant treatment decisions. The purpose of this study was to identify prognostic factors for PDAC arising in IPMN and determine the benefit of postoperative adjuvant therapy. METHODS: Forty-four patients without previous therapy who underwent surgery for invasive PDAC arising in association with IPMN at our institution were identified. Medical records were reviewed for clinical and pathologic features, adjuvant therapy, and outcomes. RESULTS: On univariate analysis, positive nodes (hazard rate [HR] 14, 95% confidence interval [CI] 4.2-44), CA 19-9 > 80 (HR 6.2, 95% CI 2.2-17), lymphovascular invasion (HR 4.7, 95% CI 1.5-15), perineural invasion (HR 3.9, 95% CI 1.5-10), and positive margins (HR 3.1, 95% CI 1.2-8.0) were associated with inferior cancer-specific survival. Patients with positive nodes who received adjuvant therapy had higher median cancer-specific survival (20 months) than those who received no adjuvant therapy (3.3 months). CONCLUSIONS:Patients with PDAC arising in IPMN presented at an earlier stage than is reported for classical PDAC. Adjuvant chemoradiotherapy was associated with improved overall and cancer-specific survival for patients with advanced disease. These hypothesis-generating results require validation in a larger prospective trial.
Authors: Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess Journal: JAMA Date: 2007-01-17 Impact factor: 56.272
Authors: Roberto Salvia; Carlos Fernández-del Castillo; Claudio Bassi; Sarah P Thayer; Massimo Falconi; William Mantovani; Paolo Pederzoli; Andrew L Warshaw Journal: Ann Surg Date: 2004-05 Impact factor: 12.969
Authors: Michael D'Angelica; Murray F Brennan; Arief A Suriawinata; David Klimstra; Kevin C Conlon Journal: Ann Surg Date: 2004-03 Impact factor: 12.969
Authors: Michael J Swartz; Charles C Hsu; Timothy M Pawlik; Jordan Winter; Ralph H Hruban; Mehmet Guler; Richard D Schulick; John L Cameron; Daniel A Laheru; Christopher L Wolfgang; Joseph M Herman Journal: Int J Radiat Oncol Biol Phys Date: 2009-08-03 Impact factor: 7.038
Authors: Chandrajit P Raut; Karen R Cleary; Gregg A Staerkel; James L Abbruzzese; Robert A Wolff; Jeffrey H Lee; Jean-Nicolas Vauthey; Jeffrey E Lee; Peter W T Pisters; Douglas B Evans Journal: Ann Surg Oncol Date: 2006-03-07 Impact factor: 5.344
Authors: Taylor A Sohn; Charles J Yeo; John L Cameron; Ralph H Hruban; Noriyoshi Fukushima; Kurtis A Campbell; Keith D Lillemoe Journal: Ann Surg Date: 2004-06 Impact factor: 12.969
Authors: Thula Cannon Walter; Ingo G Steffen; Lars H Stelter; Martin H Maurer; Marcus Bahra; Wladimir Faber; Fritz Klein; Hendrik Bläker; Bernd Hamm; Timm Denecke; Christian Grieser Journal: Eur Radiol Date: 2014-11-30 Impact factor: 5.315
Authors: Vincent Quoc-Huy Trinh; Joseph Thomas Roland; Jahg Wong; Frank Revetta; Krutika Patel; Chanjuan Shi; Kathleen E DelGiorno; Bruce D Carter; Marcus Chuan Beng Tan Journal: J Pathol Date: 2022-07-18 Impact factor: 9.883
Authors: Benedetto Mungo; Chiara Croce; Atsushi Oba; Steven Ahrendt; Ana Gleisner; Chloe Friedman; Richard D Schulick; Marco Del Chiaro Journal: Ann Surg Oncol Date: 2020-08-02 Impact factor: 5.344
Authors: Eric Chong; Bathiya Ratnayake; Bobby V M Dasari; Benjamin P T Loveday; Ajith K Siriwardena; Sanjay Pandanaboyana Journal: World J Surg Date: 2021-09-20 Impact factor: 3.352
Authors: Can Jin; Juan Li; Chuanxin Zou; Xu Qiao; Peng Ma; Di Hu; Wenqin Li; Jun Jin; Zibo Meng; Zhiqiang Liu Journal: Transl Cancer Res Date: 2020-10 Impact factor: 1.241